-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Oculis SA, a biopharmaceutical company focused on the clinical phase, is pleased to announce that the data of its two phase II trials of OCS-02 clinical concept studies are optimistic
.
OCS-02 is a novel anti-tumor necrosis factor (TNF alpha) antibody fragment used to treat dry eye and acute anterior uveitis
Dr.
Riad Sherif, CEO of Oculis, said: “The data from the two phase II trials just show that OCS-02 is expected to treat the main indications that affect the front of the eye and have a serious impact on the eyesight and health of patients
.
We are excited about this and we are These data will be presented for the first time at the ARVO online annual meeting in 2021.
Dr.
Marcia de Souza Lima, Chief Medical Officer of Oculis, added: “As can be seen in the currently approved systemic treatments, OCS-02 has anti-inflammatory and safe anti-tumor necrosis factor (TNF alpha), and topical medication is very convenient.
OCS-02 is used to treat dry eye
- Summary #3543422
- Title: TNFRl gene mutations associated with the response of patients with dry eye to local anti-tumor necrosis factor (TNF alpha) antibody fragment OCS-02
- Author: Dr.
Victor L.
Perez, OCS-02 Dry Eye Concept Study Phase II Representative - Clinicaltrial.
gov identification code: NCT02365519 (OCS-02 formerly known as LME636) - You can watch the demo video in the "Pipeline" section of the official websiteIn the second phase trial, a multicenter, randomized, vehicle-controlled, double-blind, prospective study found that OCS-02 was significantly more effective than solvents in relieving severe eye discomfort associated with dry eye (p=0.
041)
.
A pre-planned exploratory pharmacogenetic analysis showed that there is a statistically significant correlation between the response of patients with dry eye to OCS-02 and genetic biomarkers (p<0.OCS-02 is used to treat uveitis
- Summary #3522243
- Title: Effectiveness and safety of a novel local anti-tumor necrosis factor (TNF alpha) antibody OCS-02 for acute anterior uveitis (AAU): Phase II study
- Author: Anat Galor, Master of Public Health, OCS-02 Acute Anterior Uveitis Phase II Study Representative
- Clinicaltrial.
gov identification code: NCT02482129 (OCS-02 formerly known as LME636) - You can watch the demo video in the "Pipeline" section of the official website In the second phase of the trial, a multi-center, randomized, parallel group, double-blind, active control study of patients with acute anterior uveitis found that the medication of OCS-02 is effective for ocular inflammation, consistent with the previous preset standards
.
OCS-02 is well tolerated and has no steroid side effects or eye irritation
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
